Efficacy and Tolerability Of Privigen® In Clinical Practice - 24/01/14
Doi : 10.1016/j.jaci.2013.12.647
Morna J. Dorsey, Dr.MD, MMSc, FAAAAI 1, Viet Ho 2, Mohsen I. Mabudian, Dr.MD 3, Pere Soler-Palacín 4, Nerea Domínguez-Pinilla 5, Robert W. Hellmers, Dr.MD, FAAAAI 6, Radha Gandhi Rishi, Dr.MD, FAAAAI 6, Rahul Rishi 7, Duane W. Wong, Dr.MD 6, Mikhail Rojavin, Dr.PhD 8, Alphonse Hubsch, Dr. 9, Melvin Berger, Dr.MD, PhD, FAAAAI 8
1 Department of Pediatrics, University of California, San Francisco, San Francisco, CA
2 Moffitt Cancer Hospital, FL
3 Beaver Medical Group, Inc., Department of Allergy and Clinical Immunology, Redlands, CA
4 Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain
5 Department of Pediatrics, Hospital 12 de Octubre, Madrid, Spain
6 Arizona Allergy Associates, Chandler, AZ
7 Arizona Allergy Associates, Phoenix, AZ
8 Clinical Research and Development, CSL Behring LLC, King of Prussia, PA
9 CSL Behring AG, Berne, Switzerland
623
Le texte complet de cet article est disponible en PDF.Plan
© 2014
Publié par Elsevier Masson SAS.
Vol 133 - N° 2S
P. AB181 - février 2014 Retour au numéro
Article précédent
- Health-Related Quality Of Life Of Japanese Patients With Primary Immunodeficiency Diseases Receiving IgPro20, a 20% Liquid Subcutaneous Immunoglobulin (Hizentra®)
- Hirokazu Kanegane, Kohsuke Imai, Masafumi Yamada, Hidetoshi Takada, Tadashi Ariga, Ataru Igarashi, Kiichiro Tsutani, Martin Bexon, Mikhail Rojavin, Midori Kobayashi, John-Philip Lawo, Art Zbrozek, Shigeaki Nonoyama, Toshiro Hara, Toshio Miyawaki
- Safety and Tolerability Of An Intravenously Administered Alpha1-Proteinase Inhibitor (A1PI) At An Increased Infusion Rate: A Randomized, Rate Control, Placebo-Masked, Crossover Study In Healthy Adults
- Adam Haeberle, Leock Ngo, Neil Inhaber, David Gelmont, Leman Yel
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?